Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-131093
Filing Date
2024-11-26
Accepted
2024-11-26 16:55:46
Documents
1
Period of Report
2024-11-26

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 2915
  Complete submission text file 0000950170-24-131093.txt   4502
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Issuer) CIK: 0000876343 (see all company filings)

EIN.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LINEAGE CELL THERAPEUTICS, INC. 2173 SALK AVENUE, SUITE 200 CARLSBAD CA 92008
Business Address
Samuel George A. III (Reporting) CIK: 0001878732 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-12830 | Film No.: 241505010